Orchard Therapeutics plc
Orchard Therapeutics plc (ORTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ortx · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Orchard Therapeutics plc (ORTX) measures how much investors pay for each dollar of the company's trailing earnings. ORTX's current PE ratio of N/A is calculated by dividing its stock price of $16.70 by its TTM earnings per share of -$0.62.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2016 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Orchard Therapeutics plcYou ORTX | $380M | N/A | — | -$0.62 |
 Checkpoint Therapeutics, Inc. CKPT | $368M | N/A | — | -$1.42 |
 Climb Bio, Inc. CLYM | $734M | N/A | — | -$0.88 |
 Claritev Corporation CTEV | $461M | N/A | — | -$17.30 |
 G1 Therapeutics, Inc. GTHX | $378M | N/A | — | -$0.93 |
 iTeos Therapeutics, Inc. ITOS | $449M | N/A | — | -$3.32 |
 Revance Therapeutics, Inc. RVNC | $381M | N/A | — | -$3.83 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.62 | — | |
2021-12-31 FY2021 | — | $-2.93 | — | |
2020-12-31 FY2020 | — | $-15.28 | — | |
2019-12-31 FY2019 | — | $-17.53 | — | |
2018-12-31 FY2018 | — | $-102.17 | — | |
2017-12-31 FY2017 | — | $-39.37 | — | |
2016-12-31 FY2016 | — | $-18.90 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Orchard Therapeutics plc (ORTX) measures how much investors pay for each dollar of the company's trailing earnings. ORTX's current PE ratio of N/A is calculated by dividing its stock price of $16.70 by its TTM earnings per share of -$0.62.
Frequently asked questions
ORTX pe ratio · 6 questionsORTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $16.70 and TTM EPS of -$0.62. Data sourced from Financial Modeling Prep via ORTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Orchard Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09